Deferasirox-substituted hydrazide compound 10 (IC50 +/- SEM) of 0.31 +/- 0.02 0.094 +/- 0.001 10.15 +/- 1.21 0.13 +/- 0.02 0.94 +/- 0.11 microM against AChE, MAO-A, MAO-B and COX-2
Type : Monoamine-oxidase-inhibitor, Multitarget, Triazol, Benzoate
Chemical_Nomenclature : N-(2-amino)-4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzamide
Canonical SMILES : C1=CC=CC(=C1O)C2=N[N](C(=N2)C3=C(C=CC=C3)O)C4=CC=C(C=C4)C(=O)NN
InChI : 1S\/C21H17N5O3\/c22-24-21(29)13-9-11-14(12-10-13)26-20(16-6-2-4-8-18(16)28)23-19(25-26)15-5-1-3-7-17(15)27\/h1-12,27-28H,22H2,(H,24,29)
InChIKey : MJFVTYCLTPPDDQ-UHFFFAOYSA-N
Other name(s) :
Families : Deferasirox-aminobenzamide-Cpd11 ligand of proteins in family
ACHE
Protein :
human-ACHE
Title : Exploration of novel triazolo-thiadiazine hybrids of deferasirox as multi-target-directed anti-neuroinflammatory agents with structure-activity relationship (SAR): a new treatment opportunity for Alzheimer's disease - Shakir_2025_RSC.Adv_15_101 |
Author(s) : Shakir SA , Rashid U , Marryum , Fatima N , Ejaz SA , Fayyaz A , Ullah MZ , Saeed A , Khan A , Al Harrasi A , Mumtaz A |
Ref : RSC Adv , 15 :101 , 2025 |
Abstract : |
PubMedSearch : Shakir_2025_RSC.Adv_15_101 |
PubMedID: 39758929 |